Moderna Competitors and Similar CompaniesClear all

Moderna's competitors and similar companies include Alnylam.
Moderna
Moderna
Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
Alnylam
Alnylam
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
Founding Date
Founding Date
2010
Founding Date
2002
Type
Type
Public
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Melbourne, AU
Paris, FR
München, DE
Tokyo, JP
Seoul, KR
Warszawa, PL
see more
Locations
Cambridge, US HQ
Paris, FR
Milan, IT
Tokyo, JP
Amsterdam, NL
Stockholm, SE
Zug, CH
see more
Employees
Employees
5,60044% increase
Employees
1,32324% increase
Valuation ($)
Valuation ($)
21.2 b
Valuation ($)
36.5 b

Financial

Revenue (est.)
Revenue (est.)
$3.2b (FY, 2024)
Revenue (est.)
$2.2b (FY, 2024)
Cost of goods
Cost of goods
$1.5b (FY, 2024)
Cost of goods
$306.5m (FY, 2024)
Gross profit
Gross profit
$1.8b (FY, 2024)
Gross profit
$1.9b (FY, 2024)
Net income
Net income
($3.6b) (FY, 2024)
Net income
($278.2m) (FY, 2024)

Funding

Total funding raised
Total funding raised
$ 1.8b
Total funding raised
$ 1.5b
For sources of this data, please see the company profile

View Company Profiles

Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase

Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.

View company